AssayMetrics and Cambridge Research Biochemicals Collaborate
News Oct 08, 2012
AssayMetrics Ltd has announced collaboration with Cambridge Research Biochemicals Ltd, the UK’s most established peptide and antibody company.
Fluorescence Lifetime is a new and assay technology used in the biochemical screening of new drugs in High Throughput Screening and compound characterization roles in the pharmaceutical industry.
The collaboration involves Cambridge Research Biochemicals making key peptide substrates labelled with AssayMetrics’ Fluorescence Lifetime dyes.
The peptides are used to screen novel drugs in equipment such as AssayMetrics’ Fluospec® FL reader and are employed in assays involving kinases, proteases, protein:protein interactions and other target enzyme systems.
The collaboration brings together two companies leading their respective fields to be able to offer solutions to the pharmaceutical industry enabling faster, more efficient and cheaper drug discovery and development, thereby improving the effectiveness of pharmaceutical R&D.
Dr Pierre Graves, MD of AssayMetrics Ltd commented, “This is exciting news as Cambridge Research Biochemicals have considerable expertise in making the type of complex peptides needed for innovative discovery.”
Emily Humphrys, Commercial Director of Cambridge Research Biochemicals was equally positive: “This technology has so much potential that we are really pleased to be collaborating with AssayMetrics at this early stage.”
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE